Skip to main content

Vaxcyte, Inc.

PCVX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001649094

In the last 90 days, Vaxcyte, Inc. insiders filed 0 open-market purchases and 8 sales; 331 institutions reported holding it in 13F filings for Q2 2026, worth $9.71B in total; Maverick Capital is the only superinvestor holding it.

Q1 2022 vs. Q4 2021

How the institutions holding Vaxcyte, Inc. changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of PCVX: Q4 2021 compared with Q1 2022
MeasureQ4 2021Q1 2022Change
Holders8788+1
Shares44.7M49.9M+5.13M (+11.5%)
Value$1.06B$1.20B+$140.4M (+13.2%)

New holders (12)

Institutions that held Vaxcyte, Inc. at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to PCVX in Q1 2022
InstitutionSharesValue% of portfolio
Frazier Life Sciences Management, L.P.2,309,554$55.8M4.75%
Driehaus Capital Management LLC90,000$2.17M0.03%
Victory Capital Management Inc89,010$2.15M0.00%
Walleye Capital LLC69,452$1.68M0.05%
Alyeska Investment Group, L.P.52,100$1.26M0.01%
Barclays PLC49,800$1.20M0.00%
Fred Alger Management, LLC9,677$234.0K0.00%
Amalgamated Bank5,357$129.0K0.00%
Amalgamated Financial Corp.5,357$129.0K0.00%
Zurcher Kantonalbank (Zurich Cantonalbank)4,966$120.0K0.00%
Allspring Global Investments Holdings, LLC1,161$28.0K0.00%
Lindbrook Capital, LLC69$2.00K0.00%

Sold out (11)

Institutions that held Vaxcyte, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.

Institutions that sold out of PCVX in Q1 2022
InstitutionShares, Q4 2021Value, Q4 2021
Frazier Management LLC2,309,554$54.9M
Woodline Partners LP97,396$2.32M
Gyon Technologies Capital Management, LP31,342$746.0K
Ergoteles LLC12,811$305.0K
SG Americas Securities, LLC10,155$242.0K
Prudential Financial Inc9,920$236.0K
Parametric Portfolio Associates LLC9,565$228.0K
Amundi5,795$115.0K
Quantbot Technologies LP1,800$42.0K
CWM, LLC22$1.00K
Signaturefd, LLC9$0